MaxCyte, Inc. Exercise of options and PDMR dealing

RNS Number : 3079D

MaxCyte, Inc.

06 September 2024

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Exercise of options and PDMR dealing

 

ROCKVILLE, MD, September 6, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that between 3 September 2024 and 4 September 2024, as per a filing lodged with the U.S. Securities and Exchange Commission, Stanley Erck, a Non-Executive Director of the Company, exercised options over 47,689 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 47,689 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by Stanley Erck at a price range between $3.900 and $4.300 per Common Stock ("Sale"). The sold shares represent approximately 6.9% of Stanley Erck's total equity and option holdings in the Company's stock capital, respectively.

 

Following the Exercise and Sale, Stanley Erck holds 247,751 shares of Common Stock representing 0.2% of the issued stock capital of the Company. Following the Exercise, Stanley Erck holds a further 371,879 options over Common Stock and 21,367 restricted stock units.

 

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Stanley Erck on 12 March 2024 relating solely to the sale of shares acquired from exercise of options that expire on 11 November 2024.

 

 

MaxCyte Contacts:

 

US IR Adviser Gilmartin Group David Deuchler, CFA	[phone] [e-mail]
Nominated Adviser and Joint Corporate Broker Panmure Liberum Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	[phone]
UK IR Adviser ICR Consilium Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
	Identification code	US57777K1060
b)	Nature of the transaction	Exercise of Options over common stock
c)	Price(s) and volume(s)
			Exercise Price(s)	Volume(s)
			$0.040	17,922
d)	Aggregated information
	- Aggregated volume	17,922
	- Price	$0.040
e)	Date of the transaction	3 September 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

 

 

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
	Identification code	US57777K1060
b)	Nature of the transaction	Sale of common stock
c)	Price(s) and volume(s)
			Exercise Price(s)	Volume(s)
			$4.0400	1283
			$4.0500	867
			$4.0550	75
			$4.0600	1277
			$4.0650	547
			$4.0700	2471
			$4.0800	2030
			$4.0850	525
			$4.0900	2100
			$4.0950	281
			$4.1000	2679
			$4.1100	372
			$4.1150	82
			$4.1250	69
			$4.1300	365
			$4.1350	250
			$4.1400	894
			$4.1450	201
			$4.1500	100
			$4.1550	32
			$4.2100	101
			$4.2200	200
			$4.2400	100
			$4.2500	412
			$4.2600	100
			$4.2700	200
			$4.2800	1
			$4.2900	200
			$4.3000	108
d)	Aggregated information
	- Aggregated volume	17,922
	- Price	$4.0978
e)	Date of the transaction	3 September 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq
1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
	Identification code	US57777K1060
b)	Nature of the transaction	Exercise of Options over common stock
c)	Price(s) and volume(s)
			Exercise Price(s)	Volume(s)
			$0.040	29,767
d)	Aggregated information
	- Aggregated volume	29,767
	- Price	$0.040
e)	Date of the transaction	4 September 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
	Identification code	US57777K1060
b)	Nature of the transaction	Sale of common stock
c)	Price(s) and volume(s)
			Exercise Price(s)	Volume(s)
			$3.9000	416
			$3.9050	445
			$3.9100	1060
			$3.9150	3925
			$3.9200	5733
			$3.9250	250
			$3.9300	501
			$3.9400	2267
			$3.9450	400
			$3.9500	600
			$3.9550	200
			$3.9600	500
			$3.9650	200
			$3.9700	632
			$3.9800	1400
			$4.0000	415
			$4.0100	300
			$4.0200	3544
			$4.0300	1637
			$4.0350	1620
			$4.0400	500
			$4.0500	3159
			$4.0700	63
d)	Aggregated information
	- Aggregated volume	29,767
	- Price	$3.9686
e)	Date of the transaction	4 September 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

DSHEAKNKEEALEFA